CAMP and infection: The role of LL-37 and engineered LL-37 variants (GI-20 and 17BI) in inhibiting the infection of recombinant VSV–Ebola–GP–GFP (Glycoprotein-Green Fluorescence Protein) and wildtype EV has also been documented recently [99].